 telavancin |
| Vibativ |
Pharmaceutical
company:
Astellas Pharma US
www.vibativ.com |
Pharmacologic classification: lipoglycopeptide
Therapeutic classification: antibiotic
Pregnancy risk category: C
AVAILABLE FORMS
Lyophilized powder for injection: 250-mg, 750-mg single-use vials
INDICATIONS AND DOSAGES
Complicated skin and skin-structure infections caused by susceptible gram-positive organisms, such as Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group, or Enterococcus faecalis (vancomycin-susceptible isolates only)—
Adults: 10 mg/kg I.V. infusion every 24 hours for 7 to 14 days.
CONTRAINDICATIONS AND CAUTIONS
Use cautiously in patients with renal impairment. Avoid use in patients with prolonged QTc interval, uncompensated heart failure, or severe left ventricular hypertrophy.
INTERACTIONS
None reported.
ADVERSE REACTIONS
CNS: dizziness.
GI: abdominal pain, decreased appetite, diarrhea, nausea, taste disturbance, vomiting.
GU: foamy urine.
Skin: generalized pruritus, infusion site pain, infusion site erythema, rash.
Other: rigors.
Reactions may be common, uncommon, life-threatening,
or COMMON AND LIFE-THREATENING.
|
